Abstract
Purpose. In a previous series of 25 human osteosarcoma samples studied for MYC gene amplification, we found amplification in two cases (8%), including one arising in association with Paget's disease (pagetic osteosarcoma). Based on this observation, we further investigated the prevalence of MYC gene amplification in pagetic osteosarcomas.
Methods. MYC gene amplification was assessed by Southern blot analysis using frozen tissue samples in five cases of pagetic osteosarcoma and 53 cases of primary (non-pagetic) osteosarcoma. Amplification was considered present if the MYC copy number was six or greater.
Results. Three out of five patients (60%) with pagetic osteosarcoma showed MYC gene amplification, whereas it was present in only 5/53 patients (9.4%) with primary osteosarcoma. The incidence of MYC amplification in pagetic osteosarcoma was thus significantly higher than that in primary osteosarcoma (p = 0.016).
Discussion. The finding that MYC gene amplification may be more common in pagetic than primary osteosarcoma warrants further study and suggests pathogenetic differences between primary osteosarcomas and those arising in the setting of Paget's disease. Three of the four pagetic osteosarcomas from the present study were previously shown to be immunoreactive for p53, suggesting that p53 mutation may also be a frequent genetic lesion in these tumors.
Full Text
The Full Text of this article is available as a PDF (391.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barrios C., Castresana J. S., Kreicbergs A. Clinicopathologic correlations and short-term prognosis in musculoskeletal sarcoma with c-myc oncogene amplification. Am J Clin Oncol. 1994 Jun;17(3):273–276. doi: 10.1097/00000421-199406000-00019. [DOI] [PubMed] [Google Scholar]
- Bogenmann E., Moghadam H., DeClerck Y. A., Mock A. c-myc amplification and expression in newly established human osteosarcoma cell lines. Cancer Res. 1987 Jul 15;47(14):3808–3814. [PubMed] [Google Scholar]
- Castresana J. S., Barrios C., Gómez L., Kreicbergs A. No association between c-myc amplification and TP53 mutation in sarcoma tumorigenesis. Cancer Genet Cytogenet. 1994 Aug;76(1):47–49. doi: 10.1016/0165-4608(94)90070-1. [DOI] [PubMed] [Google Scholar]
- Galaktionov K., Chen X., Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature. 1996 Aug 8;382(6591):511–517. doi: 10.1038/382511a0. [DOI] [PubMed] [Google Scholar]
- Healey J. H., Buss D. Radiation and pagetic osteogenic sarcomas. Clin Orthop Relat Res. 1991 Sep;(270):128–134. [PubMed] [Google Scholar]
- Ikeda S., Sumii H., Akiyama K., Watanabe S., Ito S., Inoue H., Takechi H., Tanabe G., Oda T. Amplification of both c-myc and c-raf-1 oncogenes in a human osteosarcoma. Jpn J Cancer Res. 1989 Jan;80(1):6–9. doi: 10.1111/j.1349-7006.1989.tb02236.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Isfort R. J., Cody D. B., Lovell G., Doersen C. J. Comparable oncogene and tumor suppressor gene alterations in rat and human osteosarcomas. Prog Clin Biol Res. 1992;376:321–330. [PubMed] [Google Scholar]
- Kawai A., Ozaki T., Ikeda S., Oda T., Miyazaki M., Sato J., Taketa K., Inoue H. Two distinct cell lines derived from a human osteosarcoma. J Cancer Res Clin Oncol. 1989;115(6):531–536. doi: 10.1007/BF00391353. [DOI] [PubMed] [Google Scholar]
- Kochevar D. T., Kochevar J., Garrett L. Low level amplification of c-sis and c-myc in a spontaneous osteosarcoma model. Cancer Lett. 1990 Sep;53(2-3):213–222. doi: 10.1016/0304-3835(90)90216-k. [DOI] [PubMed] [Google Scholar]
- Koskinen P. J., Alitalo K. Role of myc amplification and overexpression in cell growth, differentiation and death. Semin Cancer Biol. 1993 Feb;4(1):3–12. [PubMed] [Google Scholar]
- Ladanyi M., Park C. K., Lewis R., Jhanwar S. C., Healey J. H., Huvos A. G. Sporadic amplification of the MYC gene in human osteosarcomas. Diagn Mol Pathol. 1993 Sep;2(3):163–167. [PubMed] [Google Scholar]
- Lonardo F., Ueda T., Huvos A. G., Healey J., Ladanyi M. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer. 1997 Apr 15;79(8):1541–1547. [PubMed] [Google Scholar]
- Martinsson T., Ståhl F., Pollwein P., Wenzel A., Levan A., Schwab M., Levan G. Tumorigenicity of SEWA murine cells correlates with degree of c-myc amplification. Oncogene. 1988 Oct;3(4):437–441. [PubMed] [Google Scholar]
- Masuda H., Battifora H., Yokota J., Meltzer S., Cline M. J. Specificity of proto-oncogene amplification in human malignant diseases. Mol Biol Med. 1987 Aug;4(4):213–227. [PubMed] [Google Scholar]
- Ozaki T., Ikeda S., Kawai A., Inoue H., Oda T. Alterations of retinoblastoma susceptible gene accompanied by c-myc amplification in human bone and soft tissue tumors. Cell Mol Biol (Noisy-le-grand) 1993 Mar;39(2):235–242. [PubMed] [Google Scholar]
- Perren T. J. c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer. 1991 Mar;63(3):328–332. doi: 10.1038/bjc.1991.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schwab M., Amler L. C. Amplification of cellular oncogenes: a predictor of clinical outcome in human cancer. Genes Chromosomes Cancer. 1990 Jan;1(3):181–193. doi: 10.1002/gcc.2870010302. [DOI] [PubMed] [Google Scholar]
- Schwab M., Ramsay G., Alitalo K., Varmus H. E., Bishop J. M., Martinsson T., Levan G., Levan A. Amplification and enhanced expression of the c-myc oncogene in mouse SEWA tumour cells. Nature. 1985 May 23;315(6017):345–347. doi: 10.1038/315345a0. [DOI] [PubMed] [Google Scholar]
- Seeger R. C., Brodeur G. M., Sather H., Dalton A., Siegel S. E., Wong K. Y., Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985 Oct 31;313(18):1111–1116. doi: 10.1056/NEJM198510313131802. [DOI] [PubMed] [Google Scholar]
- Sturm S. A., Strauss P. G., Adolph S., Hameister H., Erfle V. Amplification and rearrangement of c-myc in radiation-induced murine osteosarcomas. Cancer Res. 1990 Jul 1;50(13):4146–4153. [PubMed] [Google Scholar]